BizDataDive: Why does a new drug require joint R&D?
China has a third of the world's innovative drugs-in-development, while the US contributes 55% of global biopharma R&D investment.
When these strengths meet, multi-billion-dollar partnerships follow—and patients worldwide benefit.
In this episode, we explore why drug development knows no borders.
此摘要由5News从媒体的公开信息源汇聚而成。 包含完整背景的全文在www.cgtn.com — 内容归CGTN Business (oficial)所有。
